Sugi Predict

Sugi Predict / Targets / ITGB5

ITGB5

Integrin beta-5 · P18084 · ITGB5 on Sugi Atlas →

31,556 patent compounds predicted against ITGB5, 18,553 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1243228 SCHEMBL1243228 0.61 12/20
SCHEMBL547592 SCHEMBL547592 1.00 11/20
SCHEMBL547914 SCHEMBL547914 0.73 10/20
SCHEMBL276459 SCHEMBL276459 0.58 10/20
Trifluoroacetic Acid Trifluoroacetic Acid (SCHEMBL2074278) 0.51 10/20
SCHEMBL1773441 SCHEMBL1773441 0.43 10/20
SCHEMBL548056 SCHEMBL548056 0.81 9/20
SCHEMBL275079 SCHEMBL275079 0.69 9/20
Cilengitide Cilengitide (SCHEMBL34082) 0.78 8/20
SCHEMBL275146 SCHEMBL275146 0.57 8/20
SCHEMBL244383 SCHEMBL244383 1.00 7/20
SCHEMBL2043373 SCHEMBL2043373 0.60 7/20
SCHEMBL241017 SCHEMBL241017 0.59 7/20
SCHEMBL241018 SCHEMBL241018 0.59 7/20
SCHEMBL760607 SCHEMBL760607 0.57 7/20
SCHEMBL1906103 SCHEMBL1906103 0.55 7/20
SCHEMBL1825833 SCHEMBL1825833 0.83 6/20
SCHEMBL1825834 SCHEMBL1825834 0.83 6/20
SCHEMBL243383 SCHEMBL243383 0.64 6/20
SCHEMBL979390 SCHEMBL979390 0.64 6/20

Clinical trials — most relevant to ITGB5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease PHASE2UNKNOWN
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer PHASE1/PHASE2COMPLETED
[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment PHASE1/PHASE2WITHDRAWN
Cilengitide in Treating Patients With Prostate Cancer PHASE2COMPLETED
Imaging Studies and the Development of Multiple Myeloma PHASE2WITHDRAWN
Cilengitide in Treating Patients With Metastatic Prostate Cancer PHASE2COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption PHASE1COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors EARLY_PHASE1NOT_YET_RECRUITING
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer nanCOMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer nanUNKNOWN
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis nanCOMPLETED
Clinical Study of 18F-FAPI-RGD in Breast Tumors nanCOMPLETED
Integrin αvβ6-targeted PET in Malignant Tumors nanRECRUITING
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a ITGB5 binder may also engage these)

ProteinNameSimilarity
O70309 — 1.000 O70309 →
P80747 — 1.000 P80747 →
ITGB3 Integrin beta-3 0.998 landscape →
O54890 — 0.993 O54890 →
Q07441 — 0.992 Q07441 →
Q8R2H2 — 0.987 Q8R2H2 →
Q0VBD0 — 0.987 Q0VBD0 →
P26013 — 0.983 P26013 →
Q6AYF4 — 0.974 Q6AYF4 →
ITGB8 Integrin beta-8 0.974 landscape →
Q9HCM2 — 0.974 Q9HCM2 →
ITGB6 Integrin beta-6 0.973 landscape →
Q6BEA0 — 0.972 Q6BEA0 →
O75051 — 0.972 O75051 →
Q1RPR6 — 0.972 Q1RPR6 →
Q80UG2 — 0.971 Q80UG2 →
P18563 — 0.971 P18563 →
A8MWY0 — 0.969 A8MWY0 →
P70206 — 0.969 P70206 →
Q8SQB8 — 0.969 Q8SQB8 →
Q8R4G0 — 0.968 Q8R4G0 →
Q9Y2I2 — 0.968 Q9Y2I2 →
Q9Z0T9 — 0.968 Q9Z0T9 →
B8JK39 — 0.968 B8JK39 →
Q13797 — 0.968 Q13797 →
Q863C4 — 0.968 Q863C4 →
P70207 — 0.968 P70207 →
Q3UZV7 — 0.966 Q3UZV7 →
Q62919 — 0.965 Q62919 →
Q2VWQ2 — 0.965 Q2VWQ2 →